Maggie Lewis

Raxibacumab for the treatment of inhalational anthrax.

S. Ullrich, J. Mott, T. Migone, 2009, The New England journal of medicine.

Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.

N. Patel, Bin Zhou, G. Glenn, 2017, Vaccine.

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.

Bin Zhou, Nan Wang, V. Shinde, 2021, The Lancet. Infectious diseases.

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

V. Shinde, N. Patel, Haixia Zhou, 2020, The New England journal of medicine.

A Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein (EBOV GP) Nanoparticle Vaccine with Matrix-M™ Adjuvant in Healthy Adults.

S. K. Fehling, T. Strecker, G. Glenn, 2019, The Journal of infectious diseases.

First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine

V. Shinde, N. Patel, M. Frieman, 2020, medRxiv.

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.